News Bulletin
Monday, September 21st, 2026
Evening Edition
Economic Numbers:
|
Time |
Event |
Actual |
Forecast |
Previous |
|
Monday, September 21, 2026 |
||||
|
6:30 |
Fed Goolsbee
Speaks |
|
|
|
|
8:30 |
Chicago Fed National Activity (Aug) |
-4.00% |
|
8.00% |
|
11:30 |
3-Month Bill Auction |
4.02% |
|
3.97% |
|
11:30 |
6-Month Bill Auction |
4.16% |
|
4.06% |
Indices
|
|
CLOSE |
50 DMA |
200 DMA |
|
DJIA |
52,048.83 |
52,871.25 |
50,126.14 |
|
NASDAQ |
27,122.09 |
26,089.56 |
24,572.04 |
|
S&P 500 |
7,764.70 |
7,621.31 |
7,186.47 |
Earnings Calendar:
(EPS: Earning Per Share / Rev: Revenue / Mkt Cap : market Capital/ BMO :
Before Market Opening /AMC : After Market Close)
|
NAME |
COMPANY |
Mkt CAP |
EPS/Forcast |
Rev/Forcast |
Time |
|
ABVX |
Abivax SA Sponsored ADR |
$9.13B |
- / -$0.92 |
- / $799.00K |
BMO |
Market
News:
The tech-heavy NASDAQ Composite was a standout, jumping 2.3% to
end at 27,122.09 points and notching its first record close since June 2. The
benchmark S&P 500 advanced 1.5% to settle at 7,765.83 points, while
the blue-chip Dow Jones Industrial Average added 0.7% to conclude at
52,050.26 points.
Nyxoah SA (Nasdaq:NYXH)
shares fell 2% in after-hours trading Monday following the announcement that
Chief Financial Officer John Landry will step down from his role effective
October 2, 2026 to pursue another professional opportunity.
Vicor Corporation (NASDAQ:VICR) shares rose
6% in after-hours trading Monday following the company’s decision to raise its
third quarter 2026 revenue guidance.
Symplr Software has
secured approximately $175 million in preferred equity from its private equity
sponsors as part of a broader restructuring that creates new debt securities
and extends repayment timelines. Second-lien lenders, including Ares Capital
Corp. (NYSE:ARCC), plan to provide $103.5 million in fresh capital
structured as a first-out second-lien loan. The loan, which ranks ahead of
other second-lien debt, will be available to all junior-ranking lenders.
Grail Inc
(NASDAQ:GRAL) shares surged 35% on Monday after FDA staff
reviewers raised no major concerns about the company’s multi-cancer blood
screening test. The FDA staff did not flag significant issues regarding the
accuracy and safety of Grail’s Galleri test, which is
designed to detect more than 50 types of cancer, according to briefing
documents released ahead of an advisory committee meeting scheduled for
Wednesday.
Moody’s Ratings upgraded Wayfair
Inc.’s (NYSE:W) corporate family rating to B1 from B3 and its probability
of default rating to B1-PD from B3-PD on Monday. The ratings agency also
upgraded Wayfair LLC’s backed senior secured notes to
B1 from B2, while maintaining the company’s speculative grade liquidity rating
at SGL-1. The outlook for both issuers is stable.
For
internal use only